BR0207443A - Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatina - Google Patents
Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatinaInfo
- Publication number
- BR0207443A BR0207443A BR0207443-5A BR0207443A BR0207443A BR 0207443 A BR0207443 A BR 0207443A BR 0207443 A BR0207443 A BR 0207443A BR 0207443 A BR0207443 A BR 0207443A
- Authority
- BR
- Brazil
- Prior art keywords
- tegafur
- carboplatin
- paclitaxel
- uracil
- tumors
- Prior art date
Links
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 title abstract 4
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 title abstract 3
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 229930012538 Paclitaxel Natural products 0.000 title abstract 3
- 190000008236 carboplatin Chemical compound 0.000 title abstract 3
- 229960004562 carboplatin Drugs 0.000 title abstract 3
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 title abstract 3
- 235000008191 folinic acid Nutrition 0.000 title abstract 3
- 239000011672 folinic acid Substances 0.000 title abstract 3
- 229960001691 leucovorin Drugs 0.000 title abstract 3
- 229960001592 paclitaxel Drugs 0.000 title abstract 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title abstract 3
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 title abstract 3
- 229960001674 tegafur Drugs 0.000 title abstract 3
- 229940035893 uracil Drugs 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title 1
- -1 URACILA Chemical compound 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27357701P | 2001-03-06 | 2001-03-06 | |
| PCT/US2002/006262 WO2002076459A1 (en) | 2001-03-06 | 2002-03-04 | Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0207443A true BR0207443A (pt) | 2004-04-06 |
Family
ID=23044526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0207443-5A BR0207443A (pt) | 2001-03-06 | 2002-03-04 | Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatina |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6770653B2 (enExample) |
| EP (1) | EP1368034A1 (enExample) |
| JP (1) | JP2005506294A (enExample) |
| KR (1) | KR20030081496A (enExample) |
| BR (1) | BR0207443A (enExample) |
| CA (1) | CA2439676A1 (enExample) |
| CZ (1) | CZ20032266A3 (enExample) |
| EE (1) | EE200300429A (enExample) |
| HR (1) | HRP20030801A2 (enExample) |
| HU (1) | HUP0303466A3 (enExample) |
| IL (1) | IL157357A0 (enExample) |
| IS (1) | IS6925A (enExample) |
| MX (1) | MXPA03007989A (enExample) |
| NO (1) | NO20033910L (enExample) |
| PL (1) | PL363967A1 (enExample) |
| RU (1) | RU2284184C2 (enExample) |
| SK (1) | SK10602003A3 (enExample) |
| WO (1) | WO2002076459A1 (enExample) |
| YU (1) | YU69903A (enExample) |
| ZA (1) | ZA200306541B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK287901B6 (sk) * | 2000-11-06 | 2012-03-02 | Pharma Mar, S. A. | Use of Ecteinascidin 743 for preparation of medicament for effective antitumor treatment |
| MXPA05009781A (es) | 2003-03-14 | 2005-10-26 | Taiho Pharmaceutical Co Ltd | Potenciador de efecto antitumoral y agente antitumoral. |
| WO2004087105A1 (en) * | 2003-04-02 | 2004-10-14 | Celator Pharmaceuticals, Inc. | Combination formulations of platinum agents and fluoropyrimidines |
| GB0312407D0 (en) * | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
| CA2545054A1 (en) * | 2003-11-14 | 2005-06-02 | Pharma Mar, S.A. | Combination therapy comprising the use of et-743 and paclitaxel for treating cancer |
| GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
| KR20050099311A (ko) * | 2004-04-09 | 2005-10-13 | 에이엔에이치 케어연구소(주) | 주사제용 항암제 조성물 |
| KR101287918B1 (ko) * | 2004-10-26 | 2013-07-19 | 오르토 바이오테크 프로덕츠 엘.피. | 엑티나시딘 ７４３과 조합된 페길화된 리포좀 독소루비신 |
| NZ554761A (en) | 2004-10-29 | 2010-01-29 | Pharma Mar Sa | Formulations comprising ecteinascidin and a disaccharide |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| HUE038768T2 (hu) | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia |
| GB0522082D0 (en) * | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| AU2008202078B2 (en) * | 2007-10-10 | 2012-05-31 | Wellkey Holdings Limited | Stability of secondary metabolite mass production through synchronized plant cell cultures |
| EP2201141A1 (en) * | 2007-10-19 | 2010-06-30 | Pharma Mar S.A. | Prognostic molecular markers for et-743 treatment |
| US9393318B2 (en) | 2010-03-29 | 2016-07-19 | Abraxis Bioscience, Llc | Methods of treating cancer |
| BR112012024590A2 (pt) | 2010-03-29 | 2016-05-31 | Abraxis Bioscience Inc | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| KR102569221B1 (ko) * | 2015-04-22 | 2023-08-21 | 신-낫 프로덕츠 엔터프라이즈 엘엘씨 | 공결정 조성물 및 그의 약제학적 용도 |
| TWI787201B (zh) | 2016-08-31 | 2022-12-21 | 日商富士軟片股份有限公司 | 抗腫瘤劑、抗腫瘤效果增強劑及抗腫瘤用套組 |
| RU2646450C1 (ru) * | 2017-05-11 | 2018-03-05 | Владимир Михайлович Курусин | Способ лечения предраковых и ранних стадий раковых заболеваний желудка |
| CA3089728C (en) | 2018-01-29 | 2023-01-10 | Fujifilm Corporation | Antitumor agent for biliary tract cancer and method for treating biliary tract cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5A (en) * | 1836-08-10 | Thomas Blanchard | Machine for mortising solid wooden shells of ships' tackle-blocks | |
| US4328229A (en) | 1978-03-29 | 1982-05-04 | Taiho Pharmaceutical Company Limited | Anti-cancer composition for delivering 5-fluorouracil to cancer tissues |
| US5534513A (en) | 1991-09-05 | 1996-07-09 | Taiho Pharmaceutical Company, Ltd. | Antitumor potentiator and antitumor composition |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| RU2194541C1 (ru) * | 2001-07-13 | 2002-12-20 | Научно-исследовательский институт онкологии Томского научного центра СО РАН | Способ комбинированного лечения больных местнораспространенным раком желудка |
-
2002
- 2002-03-04 WO PCT/US2002/006262 patent/WO2002076459A1/en not_active Ceased
- 2002-03-04 JP JP2002574974A patent/JP2005506294A/ja active Pending
- 2002-03-04 HR HR20030801A patent/HRP20030801A2/hr not_active Application Discontinuation
- 2002-03-04 IL IL15735702A patent/IL157357A0/xx unknown
- 2002-03-04 MX MXPA03007989A patent/MXPA03007989A/es unknown
- 2002-03-04 SK SK10602003A patent/SK10602003A3/sk not_active Application Discontinuation
- 2002-03-04 CA CA002439676A patent/CA2439676A1/en not_active Abandoned
- 2002-03-04 HU HU0303466A patent/HUP0303466A3/hu unknown
- 2002-03-04 EE EEP200300429A patent/EE200300429A/xx unknown
- 2002-03-04 CZ CZ20032266A patent/CZ20032266A3/cs unknown
- 2002-03-04 YU YU69903A patent/YU69903A/sh unknown
- 2002-03-04 RU RU2003129527/14A patent/RU2284184C2/ru not_active IP Right Cessation
- 2002-03-04 US US10/090,354 patent/US6770653B2/en not_active Expired - Fee Related
- 2002-03-04 BR BR0207443-5A patent/BR0207443A/pt not_active IP Right Cessation
- 2002-03-04 KR KR10-2003-7011636A patent/KR20030081496A/ko not_active Withdrawn
- 2002-03-04 PL PL02363967A patent/PL363967A1/xx not_active Application Discontinuation
- 2002-03-04 EP EP02713715A patent/EP1368034A1/en not_active Withdrawn
-
2003
- 2003-08-21 ZA ZA200306541A patent/ZA200306541B/xx unknown
- 2003-08-22 IS IS6925A patent/IS6925A/is unknown
- 2003-09-04 NO NO20033910A patent/NO20033910L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20032266A3 (cs) | 2004-02-18 |
| US6770653B2 (en) | 2004-08-03 |
| US20020173482A1 (en) | 2002-11-21 |
| HUP0303466A3 (en) | 2005-02-28 |
| EP1368034A1 (en) | 2003-12-10 |
| IS6925A (is) | 2003-08-22 |
| RU2003129527A (ru) | 2005-03-10 |
| JP2005506294A (ja) | 2005-03-03 |
| ZA200306541B (en) | 2004-11-22 |
| IL157357A0 (en) | 2004-02-19 |
| CA2439676A1 (en) | 2002-10-03 |
| NO20033910L (no) | 2003-10-23 |
| MXPA03007989A (es) | 2003-12-04 |
| HRP20030801A2 (en) | 2004-08-31 |
| YU69903A (sh) | 2006-08-17 |
| PL363967A1 (en) | 2004-11-29 |
| KR20030081496A (ko) | 2003-10-17 |
| EE200300429A (et) | 2003-12-15 |
| SK10602003A3 (en) | 2004-10-05 |
| RU2284184C2 (ru) | 2006-09-27 |
| WO2002076459A1 (en) | 2002-10-03 |
| NO20033910D0 (no) | 2003-09-04 |
| HUP0303466A2 (hu) | 2004-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0207443A (pt) | Método e forma de dosagem para o tratamento de tumores pela administração de tegafur, uracila, ácido folìnico, paclitaxel e carboplatina | |
| WO2004006842A3 (en) | Combinations of drugs for the treatment of neoplasms | |
| MXPA03010121A (es) | Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales. | |
| MY141584A (en) | Pharmaceutical uses of bisphosphonates | |
| TW200518752A (en) | Combinations of drugs for the treatment of neoplasms | |
| SG166775A1 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
| DK1169059T3 (da) | Docetaxel i kombination med rhuMAb HER2 til behandling af cancere | |
| CY1108395T1 (el) | Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων | |
| DE50310516D1 (de) | Fredericamycin-derivate | |
| BR0010524A (pt) | Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico | |
| ATE442142T1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
| BR0315337A (pt) | Composto, formulação farmacêutica, e, método para tratar câncer | |
| DE602004025726D1 (de) | Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc). | |
| ATE406897T1 (de) | Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs | |
| EA200501166A1 (ru) | Составы и способы лечения тромбоцитемии | |
| DE60311788D1 (de) | Kombinationstherapie zur behandlung von krebs | |
| WO2004007676A3 (en) | Combination therapy for the treatment of neoplasms | |
| TW200603804A (en) | Treatment with irinotecan (cpt-11) and an EGFR-inhibitor | |
| BR0309996A (pt) | Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias | |
| TW200608959A (en) | Treatment with oxaliplatin and an egfr-inhibitor | |
| ATE345805T1 (de) | Calciumtrifluoracetat mit zytotoxischer wirkung | |
| BR0308911A (pt) | Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto | |
| DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen | |
| WO2004017919A3 (en) | Use of mullerian inhibiting substance and interferon for treating tumors | |
| HK1060518A (en) | Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15K | Others concerning applications: alteration of classification |
Free format text: PARA.INT.CI.A61K 31/505, 461K 31175, A61P 35/00 Ipc: A61K 31/505 (2011.01), A61K 31/175 (2011.01), A61P |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A E 9A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011. |